Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Sutent Prescribers for RCC: Oncologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
January 28, 2008
Boehringer Ingelheim today announced that the Committee for Medicinal Products in Human Use (CHMP) of the European Medicines Agency has issued a positive opinion to recommend marketing authorisation of their novel, oral direct thrombin inhibitor, dabigatran etexilate. May well replace current agents!
Analysis of: European Medicines Agency recommends approval of novel oral anticoagulant, dabigatran etexilate | www.pipelinereview.com
Author: GLG Expert Contributor
An Oral agent that can be used as an alternative to the cumbersome Warfarin as well as low molecular weight heparin.
January 28, 2008
Drug reps: a double edged sword?
Analysis of: 19 Percent of Office-Based Physicians Refuse to See Pharmaceutical, Biotech and Medical Device Sales Reps | www.drugs.com
Author: GLG Expert Contributor
Physicians are seeing less and less of pharmaceutical company reps due to personal as well as institutional restrictions.
January 25, 2008
Amgen's prospects?? +/-?
Analysis of: Amgen Shows Little Growth | online.wsj.com
Author: GLG Expert Contributor
A monoclonal antibody may "rescue" Amgen from the fall off in erythropoietin use.
January 24, 2008
XL139: BMS gamble??
Analysis of: Exelixis and Bristol-Myers Squibb to Co-Develop XL139, an Inhibitor of the Hedgehog Pathway | www.prnewswire.com
Author: GLG Expert Contributor
BMS is basically taking a flyer that  this new targeting agent will be clinically efficacious.
January 21, 2008
ARIAD Pharmaceutical's Deforolimus: mTOR inhibition revisited
Analysis of: Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies | jco.ascopubs.org
Author: GLG Expert Contributor
Deforolimus is an analog of rapamycin that has been shown to inhibit mTOR activity. This is only a phase I trial and is rather dated but still points to potential efficacy. The editorial in the JCO http://jco.ascopubs.org/cgi/content/full/26/3/348   points to the hopes and future for this...
January 18, 2008
Rituxan: A slightly new twist. Beneficial to who??
Analysis of: Rituximab Combined with CHOP Improves Survival in Older Lymphoma Patients | www.medscape.com
Author: GLG Expert Contributor
Rituxan added to CHOP chemo in aggressive NHL and given at 2 week rather than 3 week intervals is as effective and safe as the standard Q 3 week program in older (61-80) patients 
January 17, 2008
Prostate cancer: Will it be used? Yes!! Will the insurers pay for early detection??
Analysis of: $300 to Learn Risk of Cancer of the Prostate | www.nytimes.com
Author: GLG Expert Contributor
We can now determine with genetic tests who is at risk for developing PC. ProActive Genetics. The more genetic variants found, the greater the risk of PC. 4 or 5 variants increased ones risk x 4.5.
January 17, 2008
Vidaza use in the EU. I'm surprised it wasn't already in use.
Analysis of: Pharmion Submits European Marketing Authorization Application (MAA) For Vidaza(R) In Patients With Higher Risk Myelodysplastic Syndromes (MDS) | www.medicalnewstoday.com
Author: GLG Expert Contributor
Pharmion's Vidaza is seeking approval for use in higher risk myelodysplasia (MDS) in the EU.
January 15, 2008
Neuropilin-2 : An interesting class of agents
Analysis of: Neuropilin-2 May Offer New Therapeutic Target in Colon Cancer | www.medscape.com
Author: GLG Expert Contributor
Targeting this protein MAY offer a therapeutic alternative or "add on" in GI malignancies.
Donald FlemingJanuary 14, 2008
Amgen's questionable future
Analysis of: Amgen's Outlook Brightens | online.wsj.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Amgen hit hard by recent ESA reimbursement requirements Amgen Has Neulasta, but is this a sure winner Amgen has no dynamite in near future

Previous Page : 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 Next181 to 190 of 506

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203